Nasal NK/T-cell lymphoma is a type of extranodal non-Hodgkin’s lymphoma with a high prevalence in Asia and South America, but less common in Western countries, and is named “nasal, nasal NK/T-cell lymphoma” in the World Health Organization (WHO) classification of lymphoid neoplastic diseases. The disease is most common in young and middle-aged men, with a male-to-female ratio of about 3:1. The average age of onset is about 40 years, but elderly and pediatric patients can also be seen clinically. It is generally believed that NK/T-cell lymphoma is associated with EBV infection, is highly aggressive, has a short course, and has a rapid clinical progression with only a 6-12 month survival period if not treated promptly. Chinese physicians have more practical experience in the diagnosis and treatment of this disease because of its strong regional nature. The clinical symptoms of nasal NK/T-cell lymphoma are closely related to the site of invasion. The tumor is often confined to the nasal cavity or directly invades adjacent structures and tissues, with the nose and palate being the most common sites of development. In the early stage, the lesion is usually confined to one side of the nasal cavity, often originating from the inferior turbinate, and may invade the nasal septum, contralateral nasal cavity, paranasal sinuses, orbit, nasopharyngeal cavity, hard palate and other adjacent tissues and organs. Depending on the site of invasion, there are clinical manifestations, such as nasal congestion, blood in the nose, tinnitus, hearing loss, limited eye movement, sore throat, mucosal ulcers, and redness of the nasal and dorsal nasal bullae. Progressive necrotic lesions along the midline of the nose and face are the characteristic manifestations of the disease, so patients often exhibit a special malodor in the nasal cavity due to nasal mucosal erosion and necrosis; if the tumor infiltrates and destroys the bone, nasal septal perforation, hard palate perforation, and cavernous injury of the nasal bridge may also occur. The disease is often combined with B symptoms: fever, night sweats and weight loss >10%. The fever of this disease is characterized by high fever (which can be above 40 degrees), which is difficult to control with antibiotics and general antipyretic and analgesic drugs, but radiotherapy can effectively control the fever. A small number of patients also have a combination of enlarged lymph nodes in the neck and, in advanced stages, multi-organ involvement (bone marrow invasion, hepatomegaly, splenomegaly, etc.) with neutropenia, anemia and thrombocytopenia. Since the early stage of the disease has no specific manifestations, it is often misdiagnosed as “cold”, “rhinitis” or “deviated septum” due to nasal congestion, pus, epistaxis, etc. Therefore, the diagnosis of the disease depends not only on Therefore, besides clinical manifestations and imaging examination, the most important thing is to obtain pathological basis. Since tumor cells often invade small blood vessels, resulting in ischemic necrosis of tumor tissue, biopsy tissue is often reported as “chronic inflammatory tissue”, and the pathology positivity rate is low, so clinically some patients need to repeatedly take the material for several times before the disease is finally diagnosed. For patients with a clear pathological diagnosis, systematic staging tests are needed to clarify the clinical staging, develop an appropriate treatment plan and determine the prognosis, and to improve the following tests before treatment: 1. Hepatitis B virus and copy number examination; 6. Bone marrow aspiration, etc. Unlike other aggressive lymphomas, which are mainly treated with chemotherapy, nasal NK/T-cell lymphoma is sensitive to radiation therapy and less sensitive to chemotherapy, and radiation therapy is the main radical treatment for this disease. Currently, most scholars believe that for patients with stage I/II nasal NK/T-cell lymphoma with a clear diagnosis, radiation therapy should be given first, followed by chemotherapy after the completion of radiation therapy. This mode of treatment is more effective than chemotherapy followed by radiotherapy. Radiation therapy for nasal NK/T-cell lymphoma at a dose of 50-6 OGY can achieve complete remission or even eradication in most patients. New radiation therapy techniques, intensity-modulated radiation therapy, have been developed to increase tumor dose and protect normal tissues, showing more and more advantages. Combination chemotherapy is often required for patients with intermediate to advanced disease, but there is no uniform chemotherapy regimen internationally, and CHOP or CHEOP regimens are generally preferred. High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation or bone marrow transplantation can be a treatment for recurrent nasal NK/T-cell lymphoma.